Cover Image

Safe administration of an anti-PD-1 antibody to kidney-transplant patients: 2 clinical cases and review of the literature

Antiprogrammed cell-death protein 1 (PD-1) antibodies have revolutionized therapy of metastatic melanoma and other tumors, but some subgroups of patients such as immunosuppressed patients after solid-organ transplantation, have regularly been excluded from clinical studies. We report 2 cases of kidn...

Full description

Saved in:
Bibliographic Details
Main Authors: Winkler, Julia K. (Author) , Bender, Carolin (Author) , Lang, Nina (Author) , Zeier, Martin (Author) , Enk, Alexander (Author) , Hassel, Jessica C. (Author)
Format: Article (Journal)
Language:English
Published: November 1, 2017
In: Journal of immunotherapy
Year: 2017, Volume: 40, Issue: 9, Pages: 341-344
ISSN:1537-4513
DOI:10.1097/CJI.0000000000000188
Online Access:Verlag, Volltext: https://journals.lww.com/immunotherapy-journal/Fulltext/2017/11000/Safe_Administration_of_An_Anti_PD_1_Antibody_to.4.aspx
Verlag, Volltext: http://dx.doi.org/10.1097/CJI.0000000000000188
Get full text
Author Notes:Julia K. Winkler, Ralf Gutzmer, Carolin Bender, Nina Lang, Martin Zeier, Alexander H. Enk, and Jessica C. Hassel
Description
Summary:Antiprogrammed cell-death protein 1 (PD-1) antibodies have revolutionized therapy of metastatic melanoma and other tumors, but some subgroups of patients such as immunosuppressed patients after solid-organ transplantation, have regularly been excluded from clinical studies. We report 2 cases of kidney-transplant patients who received an anti-PD-1 antibody to treat metastatic melanoma. Treatment was tolerated well with no relevant adverse events and stable kidney functions, but the melanoma progressed in both patients. Factors potentially affecting risk of allograft rejection and response to treatment, for example, immunosuppressive regimen and therapeutic sequence, are discussed on the basis of current literature. Further studies are necessary to determine the risk of allograft rejection and the therapeutic benefit of anti-PD-1 antibodies for organ-transplanted patients, in particular as these checkpoint inhibitors have become therapeutic standard in a variety of tumors other than melanoma.
Item Description:Gesehen am 09.07.2018
Physical Description:Online Resource
ISSN:1537-4513
DOI:10.1097/CJI.0000000000000188

Similar Items